| Clinical Study of BR105 Injection (NCT05351697) | BioRay Pharmaceutical Co., Ltd. | 2022-04-19 |
| IBI397 or Combination Therapies in Patients With Advanced Malignancies (NCT05245916) | Innovent Biologics (Suzhou) Co. Ltd. | 2022-04-14 |
| Safety, Tolerability, PK, PD, Immunogenicity and Efficacy of TWP-102 in Patients With Advanced Malignancies. (NCT05024305) | Shandong TheraWisdom Biopharma Co., Ltd. | 2022-03-08 |
| Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen (NCT04837196) | Astellas Pharma Global Development, Inc. | 2021-11-11 |
| A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies (NCT05048134) | Jiangsu HengRui Medicine Co., Ltd. | 2021-10-25 |
| Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing (NCT05059522) | Pfizer | 2021-09-29 |
| Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies (NCT05391022) | Constellation Pharmaceuticals | 2021-07-20 |
| The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies. (NCT04949191) | Incyte Corporation | 2021-07-08 |
| Study of IBI323 in Patients With Advanced Malignancies (NCT04916119) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-06-29 |
| To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment. (NCT04831996) | Incyte Corporation | 2021-05-04 |
| A Clinical Study of MIL93 in Solid Tumors. (NCT04671875) | Beijing Mabworks Biotech Co., Ltd. | 2021-04-21 |
| BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) (NCT04752826) | BioInvent International AB | 2021-01-25 |
| A Clinical Study of MIL95 in Advanced Malignancies. (NCT04651348) | Beijing Mabworks Biotech Co., Ltd. | 2021-01-04 |
| Safety and Efficacy of IBI322 in Chinese Subjects With Advanced Malignant Tumors (NCT04328831) | Innovent Biologics (Suzhou) Co. Ltd. | 2020-07-31 |
| A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant Tumors (NCT04353830) | Innovent Biologics (Suzhou) Co. Ltd. | 2020-05-22 |
| Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels (NCT04537715) | Epizyme, Inc. | 2020-04-23 |
| A Study of TQB3455 Tablets in Subjects With Advanced Malignancies (NCT04340427) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-04-10 |
| Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies (NCT04181788) | Pfizer | 2020-03-18 |
| A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors (NCT03995472) | Jiangsu HengRui Medicine Co., Ltd. | 2020-02-14 |
| Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (NCT04164199) | BeOne Medicines | 2019-12-19 |
| A Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant Tumors (NCT04085185) | Innovent Biologics (Suzhou) Co. Ltd. | 2019-12-04 |
| A Study of SHR-1501 in Patients With Advanced Tumors (NCT04025957) | Jiangsu HengRui Medicine Co., Ltd. | 2019-10-30 |
| A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers. (NCT03907969) | AstraZeneca | 2019-10-09 |
| A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas (NCT03763149) | Innovent Biologics (Suzhou) Co. Ltd. | 2019-02-19 |
| A Phase 1 Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI188 in Advanced Malignancies (NCT03717103) | Innovent Biologics (Suzhou) Co. Ltd. | 2019-01-10 |
| Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies (NCT03407976) | University of Utah | 2018-06-19 |
| Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies (NCT03474640) | TopAlliance Biosciences | 2018-02-21 |
| INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (NCT03277352) | Incyte Biosciences International Sàrl | 2017-11-21 |
| A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies (NCT03241173) | Incyte Biosciences International Sàrl | 2017-10-09 |
| Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies (NCT03233139) | Regeneron Pharmaceuticals | 2017-06-21 |
| A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread (NCT03158272) | Bristol-Myers Squibb | 2017-05-25 |
| Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies (NCT03126110) | Incyte Biosciences International Sàrl | 2017-04-25 |
| Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206) (NCT02959437) | Incyte Corporation | 2017-02-27 |
| A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors (NCT02923349) | Incyte Biosciences International Sàrl | 2016-10-31 |
| PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor (NCT02873390) | Ningbo Cancer Hospital | 2016-08-01 |
| Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Gastric Cancer (NCT02862561) | Shanghai International Medical Center | 2016-08-01 |
| A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors (NCT02697591) | Incyte Biosciences International Sàrl | 2016-06-20 |
| ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants (NCT02737501) | Ariad Pharmaceuticals | 2016-05-26 |
| Phase I Study of PDR001 in Patients With Advanced Malignancies. (NCT02678260) | Novartis Pharmaceuticals | 2016-02-19 |
| Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies (NCT02608268) | Novartis Pharmaceuticals | 2015-11-23 |
| Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study (NCT02520245) | Regeneron Pharmaceuticals | 2015-08-01 |
| Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies (NCT02383212) | Regeneron Pharmaceuticals | 2015-02-02 |
| An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies (NCT02265510) | Incyte Corporation | 2014-09-10 |
| A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies (NCT02013804) | MedImmune LLC | 2013-12-19 |
| Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State (NCT01930006) | Mirati Therapeutics Inc. | 2013-08-01 |
| A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1 (NCT00948961) | Celldex Therapeutics | 2009-09-01 |
| Maintenance Study on the Long Term Safety of XL999 (NCT00955084) | Symphony Evolution, Inc. | 2008-08-01 |
| A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies (NCT00741403) | Cornerstone Pharmaceuticals | 2008-08-01 |
| A Phase 1 Dose Escalation Study of IPI-493 (NCT00724425) | Infinity Pharmaceuticals, Inc. | 2008-07-01 |
| Safety Study of Oral MGCD265 Administered With Interruption to Subjects With Advanced Malignancies (NCT00679133) | Mirati Therapeutics Inc. | 2008-04-01 |
| Everolimus and Capecitabine in Patients With Advanced Malignancy (NCT01079702) | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 2008-04-01 |
| A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies (NCT00651664) | Millennium Pharmaceuticals, Inc. | 2007-10-22 |
| A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors (NCT00500903) | Millennium Pharmaceuticals, Inc. | 2007-05-15 |
| The Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies (NCT00468260) | Novartis Pharmaceuticals | 2007-05-01 |
| Evaluate the Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies (NCT00448396) | Novartis Pharmaceuticals | 2007-03-01 |
| Pharmacokinetics of Patupilone After a Single Intravenous Administration in Patients With Advance Solid Tumor Malignancies. (NCT00426140) | Novartis Pharmaceuticals | 2006-08-01 |
| A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function (NCT00421044) | Novartis Pharmaceuticals | 2006-05-01 |
| A Phase 1 Trial of Extended MLN8054 Dosing in Patients With Advanced Malignancies (NCT00652158) | Millennium Pharmaceuticals, Inc. | 2006-04-01 |
| A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function (NCT00420524) | Novartis Pharmaceuticals | 2006-01-01 |
| PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies (NCT00611793) | SCRI Development Innovations, LLC | 2004-10-01 |
| Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignancies (NCT00083525) | Heidelberg Pharma AG | 2004-05-01 |
| An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer (NCT02784158) | Ariad Pharmaceuticals | |